Future Management of Chronic Myeloid Leukemia
Closing out their discussion on the management of chronic myeloid leukemia, experts share practical advice and excitement for novel strategies.
Monitoring Patients With Chronic Myeloid Leukemia
Moshe Talpaz, MD, discusses best practices in monitoring patients with CML and applying multidisciplinary care.
Treatment for CML: Dose Adjustment or Discontinuations
Daniel DeAngelo, MD, PhD, provides his perspective on improving CML care through dose adjustment or treatment discontinuation.
An Overview of CML Treatment Toxicities
An overview of the general toxicities patients may experience while undergoing therapy for chronic myeloid leukemia.
Chronic Myeloid Leukemia: Asciminib’s Toxicity Profile
A brief review of asciminib’s toxicity profile and how to best manage adverse events in patients with chronic myeloid leukemia.
CML Management: Personal Experience With Asciminib
Experts share their personal experience with asciminib as later-line therapy for patients with chronic myeloid leukemia.
CML: Asciminib Use in Later-Line Chronic Myeloid Leukemia
Shared insight on asciminib’s role in chronic myeloid leukemia in light of available clinical data.
CML: Third-Line Treatment Options for Chronic Myeloid Leukemia
Jorge Cortes, MD, breaks down third-line treatment options for patients who progress with chronic myeloid leukemia.
CML: Challenges and Unmet Needs in Later-Line Therapy
A brief review of the inherent challenges in guiding patients through several lines of therapy for chronic myeloid leukemia.
Selecting Second-Line Therapy for Chronic Myeloid Leukemia
Considerations for selecting optimal second-line therapy for chronic myeloid leukemia when a patient progresses.
Role of Tyrosine Kinase Inhibitors in Treatment of CML
Daniel DeAngelo, MD, PhD, highlights the role that tyrosine kinase inhibitors play in the CML treatment paradigm.
Chronic Myeloid Leukemia: Assessing Treatment Response
Key opinion leader perspectives on assessing a patient’s response to therapy for chronic myeloid leukemia.
Chromosomal Abnormalities and Genetic Alterations in CML
Shared insight on chromosomal abnormalities and genetic alterations that influence the disease course and management of CML.
An Overview of Chronic Myeloid Leukemia (CML)
Expert overview of chronic myeloid leukemia, including considerations for the unmet needs in management as they exist today.
Well-Differentiated Systemic Mastocytosis vs Chronic Mast Cell Leukemia
The panel of experts discuss the clinical differences between well-differentiated systemic mastocytosis and chronic mast cell leukemia.
Case 4: Treatment and Management Considerations in MCL
The panel of experts in SM discuss the diagnosis and treatment of a 68-year-old female with mast cell leukemia.
Case 3: Indolent Systemic Mastocytosis
Dan DeAngelo, MD, PhD, presents the case of a patient with indolent systemic mastocytosis and urticaria pigmentosa.
Avapritinib: Approval and Clinical Practice Implications
A panel of experts share their reactions to the approval of avapritinib and discuss the clinical implications.
PATHFINDER Trial Efficacy Data
Dan DeAngelo, MD, PhD, reviews key efficacy data from the phase II PATHFINDER study.
Case 2: SM Treatment Algorithm and Supportive Care Recommendations
Patricia Lugar, MD, MS, shares an allergist’s perspective regarding treatment algorithms and supportive care recommendations for patients with systemic mastocytosis.
Case 2: Treatment and Management Considerations for SM
The panel of experts in SM discuss the diagnosis and management of a 46-year-old woman with systemic mastocytosis.
Case 2: 46-year-old Woman With SM
Dan DeAngelo, MD, PhD, presents the case of a 46-year-old woman with systemic mastocytosis and associated gastrointestinal symptoms.
Case 1: Treatment Algorithm and Supportive Care Recommendations
Patricia Lugar, MD, MS, shares treatment algorithm and supportive care recommendations for a 75-year-old man with systemic mastocytosis.
Case 1: Treatment and Management Considerations
The panel of experts in SM discuss the diagnosis and management of a 75-year-old man with systemic mastocytosis.
Case 1: 75-Year-Old Man With SM
Dan DeAngelo, MD, PhD, presents the case of a 75-year-old man with systemic mastocytosis and reviews WHO diagnostic criteria.
Considerations in SM: Hereditary Alpha Tryptasemia
Prithviraj Bose, MD, and Patricia Lugar, MD, MS, discuss the considerations and testing options for hereditary alpha tryptasemia in patients with systemic mastocytosis.
Considerations in Mast Cell Disorders
The panel of experts highlights the importance of assessing symptomology and clinical characteristics in mast cell disorders.
Systemic Mastocytosis: Epidemiology and Diagnostic Criteria
Experts in the field of mast cell disorders discuss the epidemiology and diagnostic criteria of systemic mastocytosis.
Dr Cook on Real-World Data With Bridging Therapy and Axi-Cel in Relapsed/Refractory LBCL
Dr Goy on Outcomes From An Expanded Access Study of Brexu-Cel in Relapsed/Refractory MCL
Ide-Cel Provides HRQOL Benefits Over Standard Regimens in R/R Multiple Myeloma
Bridging Therapy Prior to Axi-Cel Produces Favorable Real-World Outcomes in R/R LBCL
2 Clarke Drive Cranbury, NJ 08512